Eagle Pharmaceuticals, Inc.
—Price / book
Market cap
—
Tangible equity (USD)
$70.20M
Price / tangible book
—
Price / book
—
Net income / ending equity
15.3%
Net income / ending assets
8.8%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: EGRX stock price vs HRB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HRB's multiple
Needs HRB P/E.
Implied fair value · at EGRX's multiple
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
19 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity (USD)
$70.20M
Price / tangible book
—
Price / book
—
Net income / ending equity
15.3%
Net income / ending assets
8.8%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity (USD)
-$962.04M
Price / tangible book
—
Price / book
—
Net income / ending equity
624.4%
Net income / ending assets
22.5%
Efficiency ratio
—
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Eagle Pharmaceuticals, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
H&R Block, Inc. · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
EGRX vs PFE
Merck & Co., Inc.
EGRX vs MRK
JOHNSON & JOHNSON
EGRX vs JNJ
ELI LILLY & Co
EGRX vs LLY
AMGEN INC
EGRX vs AMGN
BRISTOL MYERS SQUIBB CO
EGRX vs BMY
INTUIT INC.
EGRX vs INTU
AUTOMATIC DATA PROCESSING INC
EGRX vs ADP
PAYCHEX INC
EGRX vs PAYX
Block, Inc.
EGRX vs SQ
Blucora, Inc.
EGRX vs BCOR
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.